Dr. Carlos Gómez Martín

Dr. Carlos Gómez Martín

Unidad de Tumores Digestivos.

  • Jefe de Sección Servicio Oncología Médica.
  • Miembro de ASCO.
  • Miembro de ESMO.
  • Miembro de SEOM.
  • Miembro de GEMCAD.

Formación académica

Julio 1993
Licenciado en Medicina y Cirugía

Universidad Autónoma de Madrid
Hospital Universitario “La Paz”. Madrid

Diciembre 1998
Especialista en Oncología Médica

Servicio de Oncología Médica
Hospital Universitario "12 de Octubre". Madrid

Septiembre 2001
European Certification in Medical Oncology

Lisboa
European Society of Medical Oncology

Julio 2010
Doctor en Medicina (Sobresaliente Cum laude)

Universidad Autónoma de Madrid

Publicaciones científicas

Nº total: 42

Publicaciones más destacadas:

  1. A Diaz-Serrano, B Dominguez, C Dominguez, R Pazo-Cid, A Salud, P Jimenez-Fonseca, A Leon, MC Galan, M Alsina, F Rivera, C Plaza, L Paz-Ares, F Lopez-Rios, C Gomez-Martin. Genomic Profiling of HER2-positive Gastric Cancer. PI3K/Akt/mTOR pathway as Predictor of Outcomes in HER2-positive Advanced Gastric Cancer Treated with Trastuzumab. The Oncologist 2018 (accepted for publication)
  2. Ana Custodio, Alberto Carmona-Bayonas, Paula Jiménez Fonseca, Maria Luisa Sánchez, Antonio Viudez, Raquel Hernández, JUANA MARIA CANO, Isabel Echavarría, Carles Pericay, Monserrat Mangas, Laura Visa, Elvira Buxó, Teresa García García, Alberto Rodríguez Palomo, Felipe Álvarez Manceñido, Alejandra Lacalle, Ismael Macías, Aitor Azkarate, Avinash Ramchandani, Ana Fernández Montes, Carlos López, Federico Longo, Rodrigo Sánchez Bayona, Maria Luisa Limón, Asunción Díaz-Serrano, Alicia Hurtado Nuño, Rosario Madero, Carlos Gómez Martín, and Javier Gallego Plazas. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. Br J Cancer 2017 Jun 6;116(12):1526-1535.
  3. C Pericay, F Rivera, C Gomez-Martin, I Nuñez, A Cassinello, E Rodrigo Imedio. Positioning of Second-Line Treatment for Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Cancer Med. 2016 Dec;5(12):3464-3474.
  4. Jiménez-Fonseca P, Carmona-Bayonas A, Sánchez Lorenzo ML, Plazas JG, Custodio A, Hernández R, Garrido M, García T, Echavarría I, Cano JM, Rodríguez Palomo A, Mangas M, Macías Declara I, Ramchandani A, Visa L, Viudez A, Buxó E, Díaz-Serrano A, López C, Azkarate A, Longo F, Castañón E, Sánchez Bayona R, Pimentel P, Limón ML, Cerdá P, Álvarez Llosa R, Serrano R, Lobera MP, Alsina M, Hurtado Nuño A, Gómez-Martin C. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Gastric Cancer. 2016 Sep 6. [Epub ahead of print
  5. Gomez-Martín C, Lopez-Rios F, Aparicio J, Barriuso J, García-Carbonero R, Pazo R, Rivera F, Salgado M, Salud A, Vázquez-Sequeiros E, Lordick F. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. Cancer Lett. 2014 Aug 28;351(1):30-40. doi: 10.1016/j.canlet.2014.05.019. Epub 2014 Jun 3.
  6. Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, Leon A, Alsina M, Visa L, Rivera F, Galan MC, Del Valle E, Vilardell F, Iglesias M, Fernandez S, Landolfi S, Cuatrecasas M, Mayorga M, Jose Paulés M, Sanz-Moncasi P, Montagut C, Garralda E, Rojo F, Hidalgo M, Lopez-Rios F. Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. J Clin Oncol. 2013 Dec 10;31(35):4445-52. doi: 10.1200/JCO.2013.48.9070. Epub 2013 Oct 14.
  7. Finn RS, Poon RT, Yau T, Klümpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J. Phase I Study Investigating Everolimus Combined With Sorafenib in Patients With Advanced Hepatocellular Carcinoma. J Hepatol. 2013 Aug 5. pii: S0168-8278(13)00544-8. doi: 10.1016/j.jhep.2013.07.029. [Epub ahead of print]
  8. B. Sangro, C. Gomez-Martin, M. Mata, M. Iñarrairaegui, E. Garralda, P. Barrera, J.I. Riezu-Boj, E. Larrea, C. Alfaro, P. Sarobe, J. J. Lasarte, J. L. Pérez-Gracia, I. Melero, J. Prieto. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013 Mar 2. doi:pii: S0168-8278(13)00144-X. 10.1016/j.jhep.2013.02.022. [Epub ahead of print]
  9. Gómez-Martín C, Salazar R, Montagut C, Gil-Martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs. 2013 Apr;31(2):390-8. doi: 10.1007/s10637-012-9830-x. Epub 2012 May 22.
  10. Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodríguez-Peralto JL, Hidalgo M, López-Ríos F. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol. 2012 Aug;65(8):751-7. doi:10.1136/jclinpath-2012-200774. Epub 2012 May 8.
  11. Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434.
  12. Gómez-Martín C, Concha A, Corominas JM, García-Caballero T, García-García E, Iglesias M, López JA, Ramón Y Cajal S, Rojo F, Palacios J, Vera-Sempere F, Aranda E, Colomer R, García-Alfonso P, Garrido P, Rivera F, López-Ríos F. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol. 2011 Sep;13(9):636-51
  13. E. García-García, C. Gómez-Martín, B. Angulo, E. Conde, A. Suárez-Gauthier, M. Adrados, C. Perna, J.L. Rodríguez-Peralto, M. Hidalgo, F. López-Ríos. Hybridization for HER2 testing in gastric carcinoma: a comparison of fluorescence in situ hybridization with a novel fully automated dual-color silver in situ hybridization. Histopathology 2011 Jul; 59(1):8-17.
  14. Manuel Hidalgo, Albert Abad, Enrique Aranda, Luis Díez, Jaime Feliu, Carlos Gómez, Antonio Irigoyen, Rafael López, Fernando Rivera and Carmen Rubio. Consensus on the treatment of pancreatic cancer in Spain. Clinical and Translational Oncology 2009; 11(5), 290-301.
  15. Y Lemos-González, F J Rodríguez-Berrocal, O J Cordero, C Gómez and M Páez de la Cadena. “Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma”. British Journal of Cancer 96, 1569-1578.200
  16. H. Cortes-Funes, C. Gómez, R. Rossell et al. “Epidermal growth factor receptor activating mutations in Spanish gefinitib-treated non-small-cell lung cancer patients”. Annals of Oncology 16:1081-1086, 2005
  17. Rocio Garcia-Carbonero, Jose I.Mayordomo, Maria V.Tornamira, Marta Lopez-Brea, Antonio Rueda, Vicente Guillen, Alberto Arcediano, Alfonso Yubero, Fernando Ribera, Carlos Gómez, Alejandro Tres, Jose L. Pérez-Gracia, Carlos Lumbreras, Javier Hornedo, Hernán Cortes-Funes, Luis Paz-Ares. Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial. J Natl Cancer Inst 93:31-8; 2001.
  18. C.Gomez-Martin, C.Sola, J.Hornedo, S.Perea, C. Lumbreras, V.Valenti, A.Arcediano, M.Rodriguez, R.Salazar, H.Cortes-Funes y M.Hidalgo. Rifampin Does Not Improve the Efficacy of Quinolone Antibacterial Prophylaxis in Neutropenic Cancer Patients: Results of a Randomized Clinical Trial. J Clin Oncol 18:2126-2134, 2000.